<DOC>
	<DOCNO>NCT01175590</DOCNO>
	<brief_summary>The objective study evaluate safety Besivance ( besifloxacin ophthalmic suspension , 0.6 % ) compare vehicle .</brief_summary>
	<brief_title>Safety Besivanceâ„¢ ( Besifloxacin Ophthalmic Suspension ) 0.6 % Compared Vehicle</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Bacterial</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>7- ( 3-aminohexahydro-1H-azepin-1-yl ) -8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid</mesh_term>
	<criteria>Subjects must clinical diagnosis acute bacterial conjunctivitis exhibit purulent conjunctival discharge ( crusty sticky eyelid ) redness least one eye . Subjects willing discontinue contact lens wear duration study . Subjects able willing comply treatment follow up/study procedure . Subjects uncontrolled systemic disease debilitate disease . Subjects known hypersensitivity contraindication Besivance , fluoroquinolones , ingredient study drug . Subjects expect require disallow concurrent systemic ocular therapy ( either eye ) prior study start . ( ie , NSAIDs , corticosteroid , mast cell stabilizer , antihistamine , decongestant antimicrobial therapy ) Subjects ocular surgery ( include laser surgery ) either eye within six week prior entry study . Subjects suspect viral allergic conjunctivitis disease condition could interfere efficacy safety evaluation study medication . Subjects suspect iritis . Subjects history recurrent corneal erosion syndrome , either idiopathic secondary previous corneal trauma dry eye syndrome . Subjects active ulcerative keratitis , specifically epithelial loss great punctate keratitis . Subjects immune compromise .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>